medicines (see box).
These complex changes aim to 'recognise the importance of world-class life-enhancing drugs to patients', protect patients from higher costs and get better value from market competition between medicines with multiple brands. 1 The changes may allow PBS and patient savings through lower priced generics, but their impact on the price of patented single-brand medicines is uncertain in our view. Chiefly this is because in future most new patented medicines will be listed in F1 with reduced reference pricing thereafter.
In Australia, overall pharmacy fees vary for products priced below the general patient co-payment ($30.70), and a Choice survey in August 2006 found a wide range in the prices pharmacies charge. 2 This was due to varied application of permissible fees under the Fourth Community Pharmacy Agreement. Australian prices for generic drugs were higher than in countries with larger markets or processes such as competitive tender. In Australia, the price a patient paid for a medicine below the general co-payment depended on the manufacturer's price, wholesale and pharmacy markups, and dispensing fees. Manufacturers could offer generic drugs to pharmacists at large discounts to the prices paid by the PBS.
The government therefore considered that it had been paying too much for these medicines. In our view, this consideration unfortunately outweighed policy concerns about the importance of maintaining the full integrity of PBS reference pricing. 1, 3 PBS prices will now be influenced by which formulary a drug is in (Table 1) . To add to the complexity, the criteria do not apply to single brand combination products, as they could have components in different formularies.
Drugs which are in F2 are categorised according to the size of the discounts to pharmacy as at 1 october 2006. When the discount was less than 25% the drug is in F2A. Drugs which were heavily discounted by more than 25% are in F2T. The suppliers of drugs in these categories will have to disclose to the Department of Health and Ageing the actual price at which they sell a brand to wholesalers or pharmacies. This requirement There are no mandatory price cuts for drugs in F1. There will be compensation for wholesalers and pharmacists for the loss of income from statutory F2 price reductions. For example, from 1 August 2008 pharmacists will receive $1.50 each time they dispense a substitutable brand that costs the patient no more than the co-payment.
Many generic drugs are already priced below the general patient co-payment, and the price reductions to drugs in F2 are expected to result in more drugs falling under the co-payment. The Pharmacy Guild of Australia estimates that the price of more than 400 brands, below the general PBS co-payment, will fall. 4 Complete price and volume data will not be available for drugs once they fall below the general PBS co-payment. Although the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee (PBAC) receives some data, prescriptions for these drugs do not appear in official statistics of PBS expenditure.
The Minister for Health and Ageing has stated that the role of the PBAC, in assessing cost-effectiveness and cost minimisation and then advising the Minister on the listing of drugs on the PBS, is not affected by the legislation. 5 Yet the responsibilities of the PBAC will be formally extended to include advice to the Minister on exemptions from mandatory price reductions. It will also advise on whether drugs are 'interchangeable on an individual patient basis', a standard more uncertain than the previous, more evidence-based, 'equivalence' tests used to determine Therapeutic Group Premiums for reference pricing.
Drugs appearing 'equivalent' on average effects measured in clinical trials, for example, may not be 'interchangeable'
for an individual patient. 3 For example, while citalopram and escitalopram were in the same reference pricing group, escitalopram was initially included in F1 and citalopram was in F2T. 6 The principle of reference pricing, that drugs with identical or similar clinical outcomes should have similar prices, is integral to the architecture of the PBS and the respect it has achieved internationally. In our view, the separation of listed drugs into two groups (F1 and F2), however this is implemented, weakens the role and fiscal benefits of referencing pricing in the PBS.
Although there will be reference pricing within F1, an effect of the changes is to insulate high priced single brand (patented) F1 drugs from price cuts and from the reference pricing that applied under previous PBS processes. 3 once a new drug is listed on the PBS as F1, its price will not be linked to the price of any similar drug in F2. F1 drugs are not interchangeable at the individual patient level with drugs that have multiple brands, so the manufacturers may be able to retain their original PBS price until the listing of a bioequivalent brand satisfies the new standards for a shift to F2. Reductions in F2 drug prices will not affect F1 prices, even where the therapeutic effect of an F2 medicine is similar though not necessarily 'interchangeable at the individual patient level'.
It is our opinion that the creation of the F1 category will, over time, result in higher prices for some patented drugs than would have been the case under previous PBS arrangements. The government's rationale for this change appears to be that failure to make such changes could result in large 'special patient contributions' or the withdrawal of single-source products from the PBS. 5 The government, Medicines Australia, the Consumers' Health Forum and several professional groups view the F1-F2 changes as a means of achieving lower prices and greater transparency in the generics market. 6 However, the expectation of price reductions flowing to consumers is premised on trust in effective competition among retail pharmacies. If direct benefits to 
Letters
Letters, which may not necessarily be published in full, should be restricted to not more than 250 words. When relevant, comment on the letter is sought from the author. Due to production schedules, it is normally not possible to publish letters received in response to material appearing in a particular issue earlier than the second or third subsequent issue.
patients from lower generic medicines prices or government support for an Australian generics industry had been the primary policy objectives, then more broadly framed legislation could have included pharmacy rewards for meeting generic dispensing targets, an incentive period of market exclusivity for the first generic market entrant, and financial incentives for patients who elect to be dispensed a generic, or for patients whose doctors are prepared to prescribe generic drugs. The role of the patented pharmaceutical industry in promoting and framing these changes is also controversial 7 , particularly if the new system allows price reductions to be deferred for some products. In response to Professor Commens, a literature search performed in consultation with our pharmacology unit failed to raise any conclusive evidence that magnesium phosphate is useful in preventing cramps in the elderly. This is not to say that biochemically proven hypomagnesaemia would not respond to supplementation, in the same way as hypocalcaemia or hypokalaemia would require calcium or potassium supplementation respectively.
Top 10 drugs
These tables show the top 10 subsidised drugs in 2006-07. The tables do not include private prescriptions. 
NPS RADAR December 2007
Strontium ranelate: The PBS listing for the osteoporosis drug strontium ranelate has been extended to allow treatment of postmenopausal women without an existing fracture and a bone mineral density T-score ≤ -3.0 (primary prevention). The latest issue of NPS RADAR describes the place in therapy of strontium relative to other anti-resorptive agents.
It also contains information on:
n the listing of the anticonvulsant drug topiramate as an alternative treatment for migraine prevention, for adults unable to tolerate beta blockers or pizotifen n updated safety information for the glitazones -rosiglitazone and pioglitazone.
See the complete reviews at www.npsradar.org.au It is also useful to carry at least one 1 L bag of normal saline, and a supply of normal saline and water for injections. 
Drugs for the doctor's bag

Current practice guidelines
Precautions with emergency drugs
With sedating drugs, there is a risk of death from respiratory depression, especially when given intravenously. It is therefore important to keep the patient under observation after administration of these drugs.
Pethidine is no longer supplied as a doctor's bag item. 6 Instead, an injectable form of tramadol is now available through the PBS.
Tramadol should not be used in patients taking a serotonergic antidepressant because of the risk of serotonin syndrome.
Doctors should be aware that ketorolac should not be given to patients with renal impairment. * order forms are obtainable from Medicare Australia, phone 13 22 90. 
Storage of drugs
Drugs must be stored in a locked bag or a locked cupboard at below 25° C. Doctor's bags should not be left in cars where the temperature will easily exceed 25° C on even a mild day.
Diphtheria and tetanus vaccine is stored in a refrigerator.
A register is required to log drugs received and drugs used (including the recipient's name). Schedule 8 drugs (opioids) must be stored in a locked, fixed, steel safe, although ampoules may be put in a locked bag for use away from the clinic. A separate book (available from the Royal Australian College of General Practitioners) is required to log Schedule 8 drugs that are received and used.
Drug (form) indications Contraindications Cautions
General practice accreditation 
Conclusion
Appropriate drugs in the doctor's bag are an essential part of general practice. The contents of the bag will be tailored to suit the needs of each practice.
Dental notes
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Drugs for the doctor's bag
Dentists do not need to stock as many emergency drugs as general practitioners, however we are required to have fully equipped and well maintained emergency equipment in our surgery.
As stated in the recently published Therapeutic Guidelines:
oral and Dental 1 , the minimum requirements for emergency situations in the dental surgery are oxygen, a disposable airway, and adrenaline. For dental practices performing more extensive procedures, or with an increased proportion of medically compromised patients, then more equipment and medications are required.
Medical emergencies in dental surgeries are uncommon so there is a risk that medications will expire before they are needed. It is incumbent on dentists to ensure that the drugs in their emergency equipment are not out of date. Ideally, there should be a system for checking emergency drug stocks and expiry dates, perhaps by a monthly inventory. Many dental practices probably already have such an inventory and it can be easily foreseen that such documentation may well become part of any potential practice audit.
Emergency drugs are not available under the Pharmaceutical
Benefits Scheme for dentists and must be purchased at full cost.
This anomaly should be redressed.
Further reading
Australian The secretion of ACTH responds to a diurnal rhythm, stress and negative feedback from circulating cortisol. Cortisol regulates metabolism, and during stress it restrains and redirects the immune system and accentuates cardiovascular responses.
The inner zona reticularis produces the adrenal androgens dehydroepiandrosterone and androstenedione.
Clinical evaluation determines which tests of adrenal function are needed. The principles of testing include:
n using basal hormone concentrations for screening n using suppression or stimulation tests to definitively diagnose hormone excess or deficiency n measuring trophic hormones to diagnose the site of endocrine lesions (for example, measuring ACTH to distinguish an adrenal from a pituitary lesion in hypocortisolism).
Testing for hypercortisolism (Cushing's syndrome)
Mild Cushing's syndrome is notoriously difficult to diagnose, but early diagnosis avoids disability and reduces mortality. 
Midnight plasma cortisol
Cortisol peaks around the time of waking, decreases rapidly through the morning and reaches a nadir around midnight. Most patients with Cushing's syndrome have early morning plasma cortisol concentrations within or slightly above the normal range.
In contrast, midnight plasma cortisol concentrations are almost always high (greater than 207 nmol/L).
Midnight salivary cortisol
Salivary cortisol concentrations reflect plasma free cortisol, but appropriate assay-specific normative values must be used for its interpretation. Internationally, cut-offs have ranged widely.
We have found a cut-off of 13 nmol/L to reliably distinguish Cushing's from non-Cushing's patients.
Low-dose dexamethasone suppression testing
A low dose of dexamethasone should suppress plasma cortisol. 
Corticotrophin-releasing hormone test
The use of corticotrophin-releasing hormone to test ACTH and cortisol reserve directly assesses pituitary and adrenal function.
other than minor flushing, corticotrophin-releasing hormone
(1 microgram/kg intravenously) rarely produces adverse effects.
The test is expensive and corticotrophin-releasing hormone is not widely available.
Testing for primary aldosteronism
Conn's syndrome is hypertension and hypokalaemia due to an aldosterone-secreting adrenal tumour, however many cases are normokalaemic. Screening for primary aldosteronism may be indicated in patients with hypertension who have spontaneous or thiazide-induced hypokalaemia. 3
Plasma aldosterone concentration:plasma renin activity ratio
A mid-morning blood sample is taken from a seated patient.
In primary aldosteronism, the plasma renin activity is reduced 
Confirming primary hyperaldosteronism
Confirmatory testing aims to demonstrate aldosterone secretory autonomy, using measurements of plasma or urine aldosterone under salt loading conditions, with or without fludrocortisone. The final step is to determine if one or both adrenals are the source of aldosterone, generally requiring adrenal vein sampling.
Adrenal incidentaloma
An unanticipated adrenal mass (incidentaloma) is found in approximately 4% of upper abdominal computed CT scans.
Clinical, imaging and biochemical evaluation is necessary to exclude malignancy and hormone excess. 4 The risk of adrenocortical cancer is very low, but adrenal metastases are common and need to be considered in patients with a history of cancer.
Conclusion
Disorders of adrenocortical function are uncommon and the symptoms often non-specific. Application of a small number of biochemical screening tests can separate those patients who do not have a disorder of adrenal function from those who require specialised assessment and more complex testing. 
Self-test questions
Drug promotion
In Australia the primary targets of drug promotion are doctors, who may be provided with gifts, offers of travel, and other inducements to prescribe. 1 More subtle promotion may include educational activities, drug samples and drug familiarisation schemes, and support for the practice such as providing a nurse to collect data.
Even though doctors generally deny that they are influenced by such approaches 2,3 , there is overwhelming evidence that advertising influences prescribing behaviour. Physicians who attend pharmaceutical events are more likely to use the products of the sponsors, even in the absence of reliable and credible evidence in their favour. 4, 5 Promotional activities in general lead to increased prescribing of drugs, acceptance of commercial rather than scientific views, a propensity to engage in non-rational prescribing behaviour 6, 7, 8 , and biases in favour of a company's drugs. 9, 10 While research undertaken by industry is often rigorous and well conducted, it may be driven by commercial imperatives leading to biased presentation and interpretation of results. 11, 12 Protocols and methodologies may reflect and support intended outcomes rather than disinterested inquiry. 13 Perhaps of even greater concern is the well documented fact that industry interests substantially influence the social agenda relating to the understanding of health and disease, sexuality, body image and lifestyles. 14, 15 What is special about drug promotion? 
Conflicts of interests
one of the key requirements of a health professional involved in interactions with industry is to be able to distinguish dualities and conflicts of interests. A duality exists where there are two or more social roles that overlap, each of which is associated with a moral imperative. A conflict exists where these imperatives are contradictory and threaten to compromise the primary goal of one of them.
A duality of interest would exist when a general practitioner involved in research is considering recruiting their own patients for a study, or when a doctor considers accepting travel assistance from a pharmaceutical company to attend a meeting with undisputed scientific content at a pleasant resort location.
The principles for responding to a duality are straightforward.
It needs to be identified and disclosed publicly to the relevant community. This community should decide whether it constitutes a conflict and, if so, this needs to be managed, usually by disengaging the two conflicting roles.
Sometimes this process of disengagement is straightforward -for example, if researchers propose to include their own patients in a research project they should in general not approach the patient themselves but leave the consent process to third parties. on other occasions, such as where a researcher has direct pecuniary interests in a product being tested, more elaborate mechanisms, such as an arm's length committee or divestment of shareholdings, may be necessary.
Regulation of drug promotion
In 
Government
Although government regulation undoubtedly plays a key role, it is a blunt instrument that may not be able to provide specific guidance for all circumstances that occur in a clinical setting. Statutory regulatory regimes are also cumbersome and bureaucratic and require elaborate and expensive systems of enforcement.
Industry
The industry itself has developed a code of conduct, which is administered through the industry peak body, Medicines
Australia. 20 
RACP recommendations
These guidelines seek to demonstrate how dualities may be managed in specific circumstances that arise in common practice. They recommend that gifts should be rejected, even items of trivial value. In general, acceptance of travel expenses is discouraged. However, where a practitioner is making a formal contribution to a meeting it may be acceptable for the organising committee to offer assistance with travel and other costs. 
RACGP recommendations
The RACGP makes similar recommendations to general practitioners but is more relaxed about doctors accepting gifts. A gift may be accepted but the patient should be the primary beneficiary and the gift should be related to the general practitioner's work. So, for instance, gifts such as a stethoscope or a textbook are acceptable, whereas gifts of a holiday, frequent flyer points, a computer or cash payments are not acceptable.
The guidelines also recommend that if a general practitioner is involved in postmarketing surveillance studies, they should make it clear to the patient that the patient's welfare is not dependent on participation in the study and they can withdraw at any time and start an alternative treatment if they wish.
The Pharmaceutical Society of Australia Code
Although very brief, the Code obligates pharmacists to avoid situations that may present a conflict of interest. Accepting inappropriate gifts is also contrary to the Code.
Conclusion
opinions differ and controversies continue about the influence of the pharmaceutical industry and the proper responses to it. The system of regulation that has evolved in Australia is complex and heterogeneous, incorporating components from government, industry, community and the professions.
Although each would on its own be insufficient, together these elements constitute a delicately balanced equilibrium that goes at least some way towards ensuring that the diverse tasks and goals set by the various stakeholders are addressed and acknowledged. Whether the balance should shift more in the direction of regulation, whether a more punitive approach would be more or less effective, how best to maintain both economic incentives and public responsibility -or even if it is possible to do so -remains uncertain. 
Conflict of interest: none declared
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Relationships between health professionals and industry: maintaining a delicate balance
The level of prescribing that occurs in the average dental practice
is not usually such that it attracts the attention of pharmaceutical companies' marketing departments. However, we are large consumers of restorative materials, medicaments and other products. We rely on a good working relationship with dental supply companies who not only offer access to these products, but are also often involved in research related to them. It is most likely that dentists are not aware of the influence that advertising, 'special offers', personal visits by company representatives, endorsements and trade shows have on our purchasing habits.
What dental practitioners purchase or prescribe should always be done on the basis of available scientific evidence with patients' interest utmost in our minds. In fact, in the majority of practices it is not the dentists who purchase these items, but rather the practice manager on the advice of the dentist, advice that may not be consistently available. Situations of conflict and duality of interest may well be relatively common in the dental profession, and these should be acknowledged and complaints. In fourteen cases no breach of the Code was found. Table 1 shows the 27 complaints in which at least one breach of the Code was found. As usual, most of the complaints were made by rival pharmaceutical companies, but 12 were made by health professionals.
Most of the breaches were for using misleading information in promotional material. Some of the larger fines were imposed on companies that had allowed the public to be exposed to their promotions. Two complaints related to a company which sponsored the national conference of a patient support
Medicines Australia Code of Conduct: breaches
group. An article, originally drafted for health professionals, but published in Reader's Digest, clearly breached the Code.
Another breach, identified by several complaints, was offering a 'money-back guarantee' to patients being treated for erectile dysfunction.
The information in the report reveals some of the sophisticated strategies companies can use. one company had used a public relations consultant to manage a campaign about a medicine
which had yet to be approved in Australia. This included sponsoring a journalist to attend an overseas conference about the drug. Issuing a media release on an unapproved drug was considered to be promotional activity which breached the Code.
The Committee had to grapple with what constitutes excessive
The story of one complaint
John S Dowden, Editor
An advertising campaign for vardenafil encouraged men with erection difficulties to seek treatment. The advertisement included the product logo and the name of the company.
The imagery, of an upright banana, was also used in the advertising to health professionals. As part of this parallel campaign, doctors and pharmacists were informed that the company would offer a money-back guarantee to patients.
I made a complaint to Medicines Australia as I believed that the advertising to the public would stimulate demand for a particular product and the money-back guarantee could be seen as an inducement. Complaints were also made by two pharmacists and the Australian Consumers' Association. 
Diagnosis
There are a range of diagnostic tests for myasthenia gravis. These include dynamic tests for measuring muscle weakness (for example, response to edrophonium or ice pack), electrical tests such as repetitive stimulation or single fibre electromyography, and measurement of antibodies to acetylcholine receptor and to muscle-specific tyrosine kinase.
Clinical manifestations
Myasthenia gravis affects some regional muscles more than 
Natural history of myasthenia gravis
Generally, myasthenia gravis is a persistent disease requiring chronic treatment. Fluctuations over the long term are the norm.
Some patients go into long-term remission spontaneouslyapproximately 15-25% after five years for those presenting with generalised disease and somewhat more for those presenting with ocular disease only. Late relapse after sustained remission also occurs, the longest reported example being after 32 years.
It should be noted that the neuromuscular junction can be reformed, unlike many parts of the nervous system. Muscle strength that has been affected by myasthenia gravis for a long time often recovers with treatment. This means that the intensity of treatment for myasthenia gravis can be modulated to the current severity of the disease. 
Treatment
The diagnosis must be confirmed before treatment, because the mainstay of treatment for most patients is immunosuppression.
Treatments to prevent the adverse effects of immunosuppression should be started simultaneously with the therapy (see Table 1 ). There is no robust evidence that long-term treatment actually cures the condition, so some patients choose 
Improve neuromuscular transmission by inhibiting acetylcholinesterase
Drugs that inhibit acetylcholinesterase include pyridostigmine, edrophonium (used only for testing) and neostigmine (for intravenous use in intensive care units only). These drugs take effect within minutes and last for hours. Although they are without long-term adverse effects, the efficacy of all Fig. 1 
Normal muscular junction
In the normal neuromuscular junction, acetylcholine released from the nerve terminal following a nerve action potential, binds to the acetylcholine receptor on the postsynaptic muscle, triggering a muscle action potential propagated by the voltage gated sodium channel. Acetylcholinesterase scavenges and breaks down unbound acetylcholine. In a separate pathway, neural agrin binds muscle specific tyrosine kinase initiating clustering of phosphorylated rapsyn and acetylcholine receptors, stabilising the postsynaptic structure opposite the nerve. 
Immunosuppression
The principal drugs used to suppress the immune system in myasthenia gravis are prednisone (a glucocorticoid) and azathioprine. The response to these treatments can take weeks to many months, with the maximal effect taking months to years. 
Azathioprine
Azathioprine is used as a steroid sparing drug and additional immunosuppressant with prednisone. In a randomised trial, after three years of treatment, 63% of patients with myasthenia gravis taking azathioprine were off all prednisone, versus 20% taking placebo, but no effect was seen in the first year. 2 Compared to the metabolic consequences of continued corticosteroids, the problems of azathioprine seem significantly less. However, the long-term consequences do include an increased risk of skin cancers and a small possible increase in the risk of haematological malignancies. About one-fifth Table 1 Prophylaxis of the complications of immunosuppression osteoporosis prevention Measure bone density before treatment and yearly while on treatment. Start calcium and vitamin D supplements. Bisphosphonates may reduce bone loss associated with the chronic use of glucocorticoids.
Cardiovascular risk Risk factor modification should be standard and includes advice to stop smoking, start an exercise program and manage hypertension.
Peptic ulcer prevention Helicobacter screening and prophylactic treatment with proton pump inhibitors or H 2 antagonists seems appropriate for those with a past history of previous ulceration or concordant use of non-steroidal anti-inflammatory drugs.
Infection prophylaxis Use of inactivated vaccines such as influenza is recommended. Live vaccines are contraindicated. A chest X-ray should be performed prior to treatment. More specific testing for tuberculosis may be indicated depending on history and chest X-ray results.
Malignancy prevention Skin cancer rates are increased in patients using azathioprine. A full yearly dermatological survey is recommended. Exhort sun protection and cancer surveillance. Regular cervical smears are recommended. Eye protection may also limit cataract development.
of patients cannot take azathioprine due to rash, hepatitis, myelosuppression, nausea or vomiting, but this is usually evident within two weeks to two months. Some doctors routinely use azathioprine for patients with generalised myasthenia gravis still requiring more than 10 mg prednisone per day at six months, or if severe disease is obvious earlier.
Other drugs
If not using azathioprine, other steroid-sparing drugs used include mycophenolate mofetil, cyclosporin, methotrexate and cyclophosphamide. Experience with these drugs is generally derived from retrospective series. none of these have proven efficacy in randomised trials except for cyclophosphamide, and choice of drug depends on age and competency of the patient plus local experience of the physician. In practice they are frequently used with apparent success, but like azathioprine the response is often slow.
Mycophenolate mofetil is a pharmacologically similar alternative to azathioprine but two recent randomised controlled trials failed to demonstrate benefit in myasthenia gravis.* The duration of both trials was less than a year. As it works in the same pathway as azathioprine this may have been inadequate and it remains widely used.
Rituximab, a monoclonal antibody specific to CD20 (on B cells), or bone marrow ablation with autologous transplant are treatments of last resort.
Remove or block autoantibodies
Plasma exchange removes autoantibodies and intravenous immunoglobulin is thought to block autoantibodies. These treatments take effect within days, but only last weeks before treatment needs to be repeated. They have a key role in stabilising severe myasthenia gravis and in preparation for surgery, or in pregnancy.
Plasma exchange is expensive and only available in major 
Self-test questions
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Treatment of myasthenia gravis
The prevalence of myasthenia gravis (about 1 in 10 000 people)
is such that every dentist will probably treat more than one patient with the condition during their career. Changes in tongue and facial muscle strength can often be the first sign of myasthenia gravis. These changes may impact on oral hygiene and the ability to wear dentures. Postural changes and the potential for the patient's medication to interact with drugs given by the dentist means that patients with myasthenia gravis have specific needs during dental treatment.
A review of the dental literature recommended that, depending on the severity of disease, patients should have multiple, ML: I lost a lot of muscle so I had to learn to walk again. When I was discharged from hospital I was in a wheelchair.
I stayed in a hotel for a month and just had to practise walking up and down the corridor, first with a frame and then with a stick. I had physiotherapy three times a week.
Going out of the hotel was difficult. I could not lift my feet over the smallest step and I fell over several times. When I went to hospital by taxi I was unable to get out of my seat. Addressing these concerns is difficult because of a lack of data.
Antipsychotic drugs in pregnancy and breastfeeding
Typical antipsychotic drugs
Studies examining the use of the older antipsychotic drugs in pregnancy have not shown a significantly increased risk of birth defects above the baseline rate of 3% in the general population. 1 There have been reports of two infants exposed to haloperidol with isolated limb defects, but they were also exposed to 
Lactation
Chlorpromazine and haloperidol are excreted in human milk in small amounts. In one report, three breastfed infants exposed to haloperidol and chlorpromazine showed developmental regression which was not seen in infants exposed to trifluoperazine alone, suggesting that use of a single antipsychotic drug poses less of a risk to a breastfed infant.
no adverse effects were reported in four infants exposed to flupenthixol via breast milk.
Atypical antipsychotic drugs
one study followed up over 150 cases of exposure to atypical antipsychotic drugs (olanzapine, risperidone, quetiapine and clozapine) in the first trimester of pregnancy. There were no differences in any of the pregnancy outcomes of interest, apart from low birth weight, which could not be explained by the study's authors. The rate of malformations in the exposed group was no greater than in the control group. 4 Animal studies have not shown an increased risk of Abatacept appears to be efficacious when given in combination with other DMARDs. 2, 3, 4, 5, 6 In a trial of patients with active disease despite methotrexate, 652 patients were randomised to also receive abatacept or placebo. After a year, 73% of patients given abatacept had a 20% clinical improvement compared to only 40% of those given placebo. There was slower radiological progression of joint damage in the abatacept group. 4 In another trial patients who had not responded to anti-TnF therapy received either abatacept or placebo with another DMARD. More patients in the abatacept group than in the control group had a 20% improvement (50% vs 20% of patients after six months). However, reduced progression of joint damage was not established in these patients. 5 Infusion-related reactions, such as dizziness and headache, are common with abatacept. In a one-year safety trial of 1441 patients, serious infections were more frequent with abatacept than with placebo (2.9% vs 1.9%). Pneumonia was the most common type of serious infection. In patients receiving other biological drugs as well as abatacept, the rate of serious infections increased to 5.8%. overall, the incidence of neoplasms was similar with abatacept compared to placebo (3.5%). However, this rate increased to 6.8% in patients who were also taking other biological drugs. In patients with chronic obstructive pulmonary disease, there were more adverse events with abatacept than with placebo. 7 As abatacept inhibits T cell activation, it may affect a patient's ability to fight infections or malignancies. Exenatide has also been studied in patients whose diabetes has not been controlled by a thiazolidinedione with or without metformin. A group of 121 patients injected exenatide and 112 injected a placebo twice daily. After 16 weeks the HbA1c had decreased by 0.89% with exenatide 10 microgram and increased by 0.09% in the placebo group. 5 After the placebo-controlled trials, 668 patients who had taken exenatide continued using it in open-label extension studies. A total of 314 patients completed a further 52 weeks of treatment.
The reduction in HbA1c seen at the end of the placebocontrolled studies was maintained. 6 In the medium-term placebo-controlled studies, more patients dropped out of the exenatide groups because of adverse effects. 2, 3, 4, 5 In the trial adding exenatide to a thiazolidinedione, 16% of the patients withdrew because of adverse effects compared with only 2% of the patients who added a placebo. 5 A common problem with exenatide is nausea. It affects more than 40% of patients some of whom will vomit. Diarrhoea and dyspepsia are also more frequent than with placebo. There is an increased frequency of hypoglycaemia when exenatide is added to regimens containing a sulfonylurea. The dose of sulfonylurea may need to be reduced.
The exenatide molecule is not identical to human GLP-1.
Some patients will develop antibodies against exenatide.
Hypersensitivity reactions may occur and it is possible that high antibody titres could reduce the efficacy of exenatide.
During the 30-week trials, patients randomised to take exenatide lost 1-3 kg in weight. 2, 3, 4 8 Gastrointestinal adverse reactions were common with exenatide and contributed to these withdrawals.
In Europe there is a risk management plan to monitor for safety concerns such as pancreatitis and anti-exenatide antibodies.
Long-term outcomes with exenatide are currently unknown.
As it is relatively expensive, the use of exenatide may be limited to obese patients with insulin resistance, but this will require further study. At present, the Australian approval is for adjunctive therapy in patients who are not achieving adequate glycaemic control with metformin, a sulfonylurea, or both. In a phase I placebo-controlled trial, the safety, antiviral activity and pharmacokinetics of telbivudine were assessed in 43 adults with HBeAg-positive chronic hepatitis B. Patients were given one of six different daily doses of telbivudine for four weeks and were followed up for 12 weeks after treatment. The antiviral activity of telbivudine, measured by quantifying serum viral DnA (using the polymerase chain reaction), appeared to be higher at doses of 400 mg or above. 2 A subsequent phase II trial compared the safety and efficacy of telbivudine (400 or 600 mg/day) and lamivudine (100 mg/day) alone or in combination, in 104 patients with HBeAg-positive chronic hepatitis B. At week 52, there was no detectable viral DnA in 61% of patients on telbivudine monotherapy compared to 32% of patients on lamivudine monotherapy (p<0.05).
Likewise, a greater proportion of patients taking telbivudine monotherapy had improved liver function (normalisation of alanine transferase) compared to those taking lamivudine monotherapy (86% vs 63%, p<0.05). Combination treatments with telbivudine were no more effective than telbivudine alone. 3 Results of a two-year multicentre phase III trial comparing telbivudine (600 mg/day) and lamivudine (100 mg/day) are currently unpublished. This trial included approximately 1300 patients with HBeAg-positive or -negative chronic hepatitis B.
Interim results suggest that viral suppression was greater in patients treated with telbivudine than in those treated with lamivudine. Improvements in liver function were not statistically different between the two treatments.
The efficacy of telbivudine has also been compared to adefovir in an open-label trial of 136 HBeAg-positive patients. After a year of treatment, there seemed to be greater viral suppression with telbivudine than with adefovir. 4 In the phase II and III trials, genetic evidence of viral resistance was found following viral breakthrough in some patients. 3 In in vitro studies, some viral strains that showed resistance to other nucleotide/nucleoside analogues, such as lamivudine or adefovir, also had reduced susceptibility to telbivudine.
The safety profiles of telbivudine and lamivudine were comparable in the phase III trial, with muscle-related symptoms being the most common treatment-emergent clinical adverse events, occurring in 2% of all patients. Creatine kinase elevations occurred in 9% of telbuvidine-treated patients and 3% of lamivudine-treated patients.
Telbivudine comes with a warning about the risk of myopathy.
Patients taking telbivudine should therefore be advised to report any unexplained muscle aches, pain, tenderness or weakness.
Treatment should be stopped if myopathy is diagnosed.
Health professionals should also be aware that discontinuing telbivudine treatment may lead to severe acute exacerbations of hepatitis B infection. Hepatic function should be monitored for a minimum of several months once therapy has been stopped.
When monitoring hepatic function in patients taking telbivudine, check for flares in alanine transferase.
